- Lobbying
- Lobbying by Univeristy of Medicine and Dentistry of New Jersey
Lobbying Relationship
Bills mentioned
H.R.3433: GRANT Act
Sponsor: James Lankford (R-Okla.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Kyle Mulroy | Legislative Correspondent, Legislative Assistant, US Senate Legislative Assistant, U.S. Senate Intern/LA Sen. Torricelli HouseWays&MeansSubComHealth Intern HouseWays&MeansSubComHealth LC, LA, US Senate LC, LA, U.S. Senate LC, LA, U.S. Senate LC, LA, Senate |
Spencer Perlman | Legislative Assistant, Dir. Constituent Relations, US House Legislative Director, U.S. House Intern/DirConstRel/LA/LD Rep. John Porter LD, LA, Dir. of Constituent Relations, US House LD, LA, Director of Constituent Relations US Hous LD, LA, Dir. of Constituant Relations, US House LA, Dir. Constituent Relations, US House LA, Dir. COnstituent Relations, US House LA, Dir. Constituent Relations, U.S. House LA, LD, House |
Brittany Stabile | n/a |
Lauren Watts | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Amendment
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Medicare
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Registration
Issue(s) they said they’d lobby about: Cancer research, access to oral health care, biosecurity research, electronic medical records infrastructure, health education, simulation research, increased reimbursement rates for health providers and health educators, funding for public and private disease research, and increased access to and funding for medical education, particularly the reauthorization of the Higher Education Act.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate